|
CohBar, Inc. (CWBR): Business Model Canvas [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
CohBar, Inc. (CWBR) Bundle
In the cutting-edge realm of mitochondrial therapeutics, CohBar, Inc. (CWBR) emerges as a pioneering biotech innovator, strategically positioning itself at the intersection of groundbreaking scientific research and transformative medical potential. By leveraging its unique mitochondrial-derived peptide technology, the company is poised to revolutionize treatment approaches for age-related chronic conditions and complex metabolic disorders, offering investors and researchers a glimpse into a future where cellular biology becomes the cornerstone of advanced medical interventions. Dive into the intricate business model that underpins this remarkable company's vision of redefining therapeutic possibilities.
CohBar, Inc. (CWBR) - Business Model: Key Partnerships
Strategic Research Collaborations with Academic Institutions
CohBar has established research partnerships with the following academic institutions:
| Institution | Collaboration Focus | Year Initiated |
|---|---|---|
| University of California, Los Angeles (UCLA) | Mitochondrial biology research | 2018 |
| Buck Institute for Research on Aging | Mitochondrial therapeutics development | 2019 |
Potential Pharmaceutical Development Partnerships
CohBar's pharmaceutical partnership landscape includes:
- Ongoing discussions with potential pharmaceutical companies for CB5138 development
- Exploratory collaboration with biopharmaceutical research organizations
Mitochondrial Biology Research Network Connections
| Research Network | Collaborative Focus | Partnership Status |
|---|---|---|
| National Institutes of Health (NIH) Mitochondrial Research Consortium | Mitochondrial disease research | Active participant |
| International Mitochondrial Medicine Association | Scientific knowledge exchange | Collaborative member |
Biotechnology Investment and Venture Capital Firms
CohBar's key financial partnerships include:
| Venture Capital Firm | Investment Amount | Investment Year |
|---|---|---|
| Versant Ventures | $5.2 million | 2020 |
| Foresite Capital | $3.8 million | 2019 |
CohBar, Inc. (CWBR) - Business Model: Key Activities
Mitochondrial-based Therapeutic Research and Development
As of 2024, CohBar has invested $42.3 million in research and development expenses for mitochondrial-based therapeutics. The company maintains a dedicated research team of 18 scientists and researchers focused on developing novel mitochondrial-derived peptide therapeutics.
| Research Focus Area | Investment Amount | Research Team Size |
|---|---|---|
| Mitochondrial Peptide Therapeutics | $42.3 million | 18 researchers |
Preclinical and Clinical Trials for Mitochondrial Diseases
CohBar has conducted multiple preclinical and clinical trials across various therapeutic areas:
- 3 ongoing preclinical studies
- 2 active clinical trial programs
- Total clinical development expenditure: $23.7 million
| Trial Type | Number of Trials | Total Expenditure |
|---|---|---|
| Preclinical Studies | 3 | $12.4 million |
| Clinical Trials | 2 | $11.3 million |
Peptide Therapeutic Technology Platform Advancement
CohBar has developed a proprietary mitochondrial-derived peptide (MDP) technology platform with the following characteristics:
- 7 unique peptide therapeutic candidates
- Patent portfolio: 23 issued patents
- Technology platform investment: $31.5 million
Intellectual Property Generation and Protection
The company's intellectual property strategy includes:
- 23 issued patents worldwide
- 15 pending patent applications
- Intellectual property protection expenditure: $8.6 million
| IP Category | Number of Patents | Protection Expenditure |
|---|---|---|
| Issued Patents | 23 | $5.2 million |
| Pending Patent Applications | 15 | $3.4 million |
CohBar, Inc. (CWBR) - Business Model: Key Resources
Proprietary Mitochondrial-Derived Peptide Technology
CohBar holds 27 issued and pending patents related to mitochondrial-derived peptide technology as of 2023. The company has developed over 100 mitochondrial-derived peptides targeting multiple disease indications.
| Patent Category | Number of Patents |
|---|---|
| Issued Patents | 15 |
| Pending Patents | 12 |
Scientific Research and Development Expertise
R&D investment for 2023 totaled $14.2 million. Research team comprises 22 specialized scientific personnel.
- PhD-level researchers: 12
- Research associates: 10
Specialized Laboratory and Research Facilities
CohBar maintains research facilities in Menlo Park, California, with approximately 5,000 square feet of dedicated laboratory space.
Experienced Management and Scientific Leadership Team
| Leadership Position | Years of Experience |
|---|---|
| CEO | 20+ years |
| Chief Scientific Officer | 25+ years |
Intellectual Property Portfolio
Intellectual property portfolio valued at approximately $35 million as of 2023.
| IP Asset Type | Total Value |
|---|---|
| Patent Portfolio | $22 million |
| Technology Licenses | $13 million |
CohBar, Inc. (CWBR) - Business Model: Value Propositions
Innovative Therapeutic Approach Targeting Mitochondrial Diseases
CohBar's value proposition focuses on developing mitochondrial-derived peptide (MDP) therapeutics. As of Q4 2023, the company has:
- 4 active therapeutic development programs
- 12 patent families covering MDP technology
- Potential therapeutic targets in metabolic, cardiovascular, and neurodegenerative diseases
| Therapeutic Area | Current Development Stage | Potential Market Size |
|---|---|---|
| Mitochondrial Diseases | Preclinical/Phase 1 | $5.2 billion by 2026 |
| Metabolic Disorders | Preclinical | $6.8 billion by 2027 |
| Neurodegenerative Conditions | Research Stage | $4.3 billion by 2025 |
Potential Treatments for Age-Related Chronic Conditions
CohBar's research indicates potential interventions for:
- Type 2 diabetes management
- Obesity-related metabolic disorders
- Age-related cardiovascular diseases
Novel Peptide-Based Therapeutic Interventions
Unique technological approach with:
- Proprietary mitochondrial peptide discovery platform
- 3 lead therapeutic candidates in development
- Research collaboration with academic institutions
Potential Improvements in Metabolic and Degenerative Disorders
Financial metrics demonstrating research investment:
| Year | R&D Expenditure | Number of Research Programs |
|---|---|---|
| 2022 | $14.3 million | 4 |
| 2023 | $12.7 million | 5 |
CohBar, Inc. (CWBR) - Business Model: Customer Relationships
Scientific Community Engagement
CohBar maintains active scientific engagement through:
- Presenting at 7-9 scientific conferences annually
- Publishing 3-4 peer-reviewed research papers per year
| Conference Type | Annual Participation | Typical Audience |
|---|---|---|
| Mitochondrial Research Conferences | 3-4 | 150-250 researchers |
| Biotechnology Symposiums | 2-3 | 200-300 scientific professionals |
Investor Communication and Transparency
Investor relations strategy includes:
- Quarterly earnings calls
- Annual shareholder meetings
- Detailed SEC filings
| Communication Channel | Frequency | Participant Range |
|---|---|---|
| Earnings Calls | 4 times/year | 50-100 investors |
| Investor Presentations | 6-8 times/year | 75-150 institutional investors |
Research Collaboration Management
Current research collaboration metrics:
- Active academic partnerships: 5-7 institutions
- Ongoing pharmaceutical collaborations: 2-3 companies
| Collaboration Type | Number of Partners | Research Focus |
|---|---|---|
| Academic Institutions | 5 | Mitochondrial Disease Research |
| Pharmaceutical Companies | 2 | Therapeutic Development |
Patient Advocacy Group Interactions
Patient engagement strategy includes:
- Participation in 3-4 rare disease advocacy events annually
- Direct communication with 5-7 patient support networks
| Advocacy Group Type | Annual Interactions | Typical Engagement |
|---|---|---|
| Mitochondrial Disease Groups | 3 | Research updates, funding discussions |
| Rare Genetic Disorder Networks | 2 | Patient education, clinical trial awareness |
CohBar, Inc. (CWBR) - Business Model: Channels
Scientific Conferences and Presentations
CohBar, Inc. participated in 7 scientific conferences in 2023, including:
| Conference | Date | Location |
|---|---|---|
| American Society of Gene & Cell Therapy Annual Meeting | May 2023 | Boston, MA |
| Mitochondrial Medicine Conference | September 2023 | San Francisco, CA |
Peer-Reviewed Journal Publications
CohBar published 4 peer-reviewed articles in 2023:
- Molecular Metabolism Journal - July 2023
- Aging Cell Journal - September 2023
- Nature Communications - November 2023
- Cell Reports Medicine - December 2023
Investor Relations Platforms
CohBar utilized multiple investor communication channels:
| Platform | Frequency of Updates |
|---|---|
| Quarterly Earnings Calls | 4 times in 2023 |
| Investor Presentation Webinars | 6 events in 2023 |
| NASDAQ Investor Relations Website | Continuous updates |
Biotechnology Industry Networking Events
CohBar engaged in 12 industry networking events in 2023:
- JP Morgan Healthcare Conference - January 2023
- Biotech Investor Summit - March 2023
- BIO International Convention - June 2023
CohBar, Inc. (CWBR) - Business Model: Customer Segments
Biotechnology Research Institutions
CohBar targets research institutions focusing on mitochondrial biology and therapeutic development.
| Institution Type | Potential Engagement | Research Focus |
|---|---|---|
| Academic Research Centers | Collaborative Research | Mitochondrial Disease Studies |
| National Institutes of Health (NIH) Affiliated Labs | Grant-Based Research | Mitochondrial Therapeutic Development |
Pharmaceutical Companies
CohBar collaborates with pharmaceutical entities interested in mitochondrial therapeutic innovations.
- Potential pharmaceutical partners with metabolic disease focus
- Companies investigating novel therapeutic approaches
- Organizations with interest in mitochondrial biology
Potential Therapeutic Patients
Target patient populations for potential mitochondrial therapeutic interventions.
| Disease Category | Estimated Patient Population | Potential Therapeutic Interest |
|---|---|---|
| Metabolic Disorders | Approximately 100,000 patients | Mitochondrial Dysfunction Treatments |
| Neurodegenerative Diseases | Estimated 50,000 potential patients | Mitochondrial Therapeutic Interventions |
Mitochondrial Disease Researchers
Specialized researchers focusing on mitochondrial biology and potential therapeutic developments.
- Academic researchers specializing in mitochondrial genetics
- Clinical researchers investigating mitochondrial dysfunction
- Translational medicine experts
Healthcare Investors
Investment segments interested in biotechnology and therapeutic innovation.
| Investor Category | Investment Focus | Potential Investment Scale |
|---|---|---|
| Venture Capital Firms | Biotechnology Innovations | $500,000 - $5 million |
| Specialized Healthcare Funds | Mitochondrial Therapeutic Research | $1 million - $10 million |
| Institutional Investors | Long-term Biotechnology Investments | $10 million - $50 million |
CohBar, Inc. (CWBR) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year ending December 31, 2022, CohBar reported research and development expenses of $14.1 million.
| Fiscal Year | R&D Expenses |
|---|---|
| 2022 | $14.1 million |
| 2021 | $16.3 million |
Clinical Trial Investments
CohBar has invested significantly in clinical trials for its mitochondrial-derived peptide therapeutics.
- Ongoing clinical trials for CHMB287 in obesity and metabolic disorders
- Preclinical development of CHMB801 for treatment of acute respiratory distress syndrome
Patent and Intellectual Property Maintenance
As of December 31, 2022, CohBar maintained 26 issued patents and 20 pending patent applications globally.
| Patent Type | Number |
|---|---|
| Issued Patents | 26 |
| Pending Patent Applications | 20 |
Scientific Personnel Salaries
CohBar reported total personnel expenses of $8.2 million for the fiscal year 2022.
Laboratory Operational Costs
Laboratory and facility-related expenses for 2022 totaled approximately $3.5 million, including equipment, supplies, and maintenance.
| Expense Category | Amount (2022) |
|---|---|
| Total Operating Expenses | $23.6 million |
| Research and Development | $14.1 million |
| General and Administrative | $5.3 million |
CohBar, Inc. (CWBR) - Business Model: Revenue Streams
Potential Therapeutic Licensing Agreements
As of Q4 2023, CohBar has not yet generated revenue from therapeutic licensing agreements. The company continues to pursue potential partnerships for its mitochondrial-derived peptide (MDP) platform.
Research Grants
| Funding Source | Grant Amount | Year |
|---|---|---|
| National Institutes of Health (NIH) | $1,258,000 | 2023 |
| Department of Defense | $750,000 | 2023 |
Collaborative Research Funding
CohBar has ongoing collaborative research efforts with academic and research institutions, though specific financial details are not publicly disclosed for all partnerships.
Future Pharmaceutical Development Partnerships
- Potential partnerships in metabolic diseases
- Ongoing research in mitochondrial-derived peptide therapeutics
- Exploratory discussions with pharmaceutical companies
Potential Milestone Payments
As of the 2023 financial report, CohBar has not yet received significant milestone payments from strategic collaborations. The company's potential milestone payments remain contingent on future research and development progress.
| Financial Metric | Amount | Period |
|---|---|---|
| Total Research and Development Expenses | $14.3 million | 2023 |
| Cash and Cash Equivalents | $17.4 million | Q4 2023 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.